Advertisement
U.S. markets open in 2 hours 15 minutes
  • S&P Futures

    5,195.50
    -19.25 (-0.37%)
     
  • Dow Futures

    39,125.00
    -98.00 (-0.25%)
     
  • Nasdaq Futures

    18,147.50
    -84.00 (-0.46%)
     
  • Russell 2000 Futures

    2,042.00
    -7.80 (-0.38%)
     
  • Crude Oil

    82.62
    -0.10 (-0.12%)
     
  • Gold

    2,157.70
    -6.60 (-0.30%)
     
  • Silver

    25.13
    -0.14 (-0.53%)
     
  • EUR/USD

    1.0848
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.63
    +0.30 (+2.09%)
     
  • GBP/USD

    1.2685
    -0.0043 (-0.34%)
     
  • USD/JPY

    150.4600
    +1.3620 (+0.91%)
     
  • Bitcoin USD

    62,616.93
    -5,531.18 (-8.12%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.61
    -15.94 (-0.21%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal

Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion.

Per the Wall Street Journal, Immunomedics — a biotech known for breast-cancer treatment Trodelvy — was initially a partner of Gilead before takeover talks began.

Terms are expected to be announced Monday.

Immunomedics, whose valuation hovers $10 billion, is just the latest in a series of deals Gilead made in 2020.

In June, Foster City, California-based Gilead acquired a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics for $275 million. Before that, it spent $4.9 billion for Forty Seven Inc., a company that makes blood cancer treatments.

Gilead closed Friday, Sept. 11 at $65.58 a share, while Immunomedics shares closed at $41.93.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement